Benign bone lesions Musculoskeletal Diseases
Conditions
Interventions
After the approval of the local ethics committee, a retrospective data analysis of the in-house software system will identify patients who were treated with Cerament® Bone Void Filler (Bonesupport™, L
Sponsors
Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who: 1. Received treatment with a ceramic biphasic bone substitute 2. For benign bone tumors and tumor-like lesions 3. With a complete set of retrospective information, including surgical protocols, X-rays, patient dismission letters and outpatient clinic protocols 4. With a minimum follow-up of 1 year after surgery
Exclusion criteria
Exclusion criteria: 1. Inconclusive data with missing surgical or histological reports
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local recurrences identified by retrospective analysis of patient charts in the timeframe between surgery and last follow-up at the outpatient clinic | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Postoperative cavity morphology changes assessed using x-rays at 6 weeks, 3 months, 6 months, 12 months, 18 months and at the last follow-up after surgery (MRI will be assessed in cases of suspected recurrence or incomplete cavity consolidation) 3. Postoperative complications assessed by review of patient charts in the timeframe between surgery and last follow-up at the outpatient clinic | — |
Countries
Austria
Outcome results
None listed